Affimed (AFMD) 6-K 10 Aug 23 2023 Q2 Unaudited consolidated interim statements of comprehensive loss Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2023
Document Information [Line Items]
Document Type	6-K
Document Period End Date	Jun. 30, 2023
Entity File Number	001-36619
Entity Registrant Name	Affimed N.V.
Entity Central Index Key	0001608390
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2

Unaudited consolidated interim

Unaudited consolidated interim statements of comprehensive loss - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Unaudited consolidated interim statements of comprehensive loss
Revenue	€ 1,390	€ 7,301	€ 5,900	€ 15,307
Other income - net	717	240	1,127	524
Research and development expenses	(25,273)	(20,829)	(54,804)	(39,208)
General and administrative expenses	(6,276)	(8,374)	(13,126)	(15,419)
Operating loss	(29,442)	(21,662)	(60,903)	(38,796)
Finance income / (costs) - net	47	2,253	(472)	2,724
Loss before tax	(29,395)	(19,409)	(61,375)	(36,072)
Income taxes	0	0	(3)	(2)
Loss for the period	(29,395)	(19,409)	(61,378)	(36,074)
Items that will not be reclassified to profit or loss
Equity investments at fair value OCI - net change in fair value	0	(599)	0	(6,773)
Other comprehensive loss	0	(599)	0	(6,773)
Total comprehensive loss	€ (29,395)	€ (20,008)	€ (61,378)	€ (42,847)
Basic loss per share in € per share	€ (0.20)	€ (0.13)	€ (0.41)	€ (0.27)
Diluted loss per share in € per share	€ (0.20)	€ (0.13)	€ (0.41)	€ (0.27)
Weighted number of common shares outstanding	149,339,335	147,326,291	149,339,335	135,385,254

Consolidated interim statements

Consolidated interim statements of financial position - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Non-current assets
Intangible assets	€ 46	€ 58
Leasehold improvements and equipment	3,518	3,823
Right-of-use assets	311	561
Total non-current assets	3,875	4,442
Current assets
Cash and cash equivalents	120,056	190,286
Trade and other receivables	2,154	2,697
Inventories	694	628
Other assets and prepaid expenses	7,932	2,459
Total current assets	130,836	196,070
TOTAL ASSETS	134,711	200,512
Equity
Issued capital	1,493	1,493
Capital reserves	590,232	582,843
Fair value reserves	(1,231)	(1,231)
Accumulated deficit	(491,568)	(430,190)
Total equity	98,926	152,915
Non current liabilities
Borrowings	9,000	11,687
Contract liabilities	774	1,083
Lease liabilities	123	176
Total non-current liabilities	9,897	12,946
Current liabilities
Trade and other payables	15,810	19,077
Borrowings	5,923	5,930
Lease liabilities	200	396
Contract liabilities	3,955	9,248
Total current liabilities	25,888	34,651
TOTAL EQUITY AND LIABILITIES	€ 134,711	€ 200,512

Unaudited consolidated interi_2

Unaudited consolidated interim statements of cash flows - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flow from operating activities
Loss for the period	€ (61,378)	€ (36,074)
Adjustments for the period:
Income taxes	3	2
Depreciation and amortization	577	703
Share-based payments	7,389	9,872
Finance income / (costs) - net	472	(2,724)
Total	(52,937)	(28,221)
Change in trade and other receivables	543	(715)
Change in inventories	(66)	(150)
Change in other assets and prepaid expenses	(5,473)	(3,873)
Change in trade, other payables, provisions and contract liabilities	(8,867)	(21,372)
Sub-total	(66,800)	(54,331)
Interest received	924	82
Paid interest	(695)	(653)
Paid income tax	(3)	(2)
Net cash used in operating activities	(66,574)	(54,904)
Cash flow from investing activities
Purchase of leasehold improvements and equipment	(11)	(194)
Cash received from the sale of financial assets	0	1,518
Net cash used for investing activities	(11)	1,324
Cash flow from financing activities
Proceeds from issue of common shares, including exercise of share-based payment awards	0	95,907
Transaction costs related to issue of common shares	0	(5,894)
Repayment of lease liabilities	(249)	(352)
Repayment of borrowings	(2,965)	(47)
Net cash used for financing activities	(3,214)	89,614
Exchange rate related changes of cash and cash equivalents	(431)	3,568
Net changes to cash and cash equivalents	(69,799)	36,034
Cash and cash equivalents at the beginning of the period	190,286	197,630
Cash and cash equivalents at the end of the period	€ 120,056	€ 237,232

Unaudited consolidated interi_3

Unaudited consolidated interim statements of changes in equity - EUR (€) € in Thousands	Issued capital	Capital reserves	Fair value reserves	Accumulated deficit	Total
Balance beginning at Dec. 31, 2021	€ 1,234	€ 474,087	€ (5,973)	€ (333,397)	€ 135,951
Issue of common shares	259	89,484			89,743
Exercise of share-based payment awards		101			101
Equity-settled share-based payment awards		9,872			9,872
Transfer of cumulative loss on sale of financial assets			2,819	(2,819)	0
Loss for the period				(36,074)	(36,074)
Other comprehensive loss			(6,773)		(6,773)
Balance ending at Jun. 30, 2022	1,493	573,544	(9,927)	(372,290)	192,820
Balance beginning at Dec. 31, 2022	1,493	582,843	(1,231)	(430,190)	152,915
Equity-settled share-based payment awards		7,389			7,389
Loss for the period				(61,378)	(61,378)
Other comprehensive loss					0
Balance ending at Jun. 30, 2023	€ 1,493	€ 590,232	€ (1,231)	€ (491,568)	€ 98,926

Reporting entity

Reporting entity	6 Months Ended
	Jun. 30, 2023
Reporting entity
Reporting entity	1. Reporting entity Affimed N.V. is a Dutch company with limited liability ( naamloze vennootschap ) and has its corporate seat in Amsterdam, the Netherlands, registered with the trade register of the Chamber of Commerce (handelsregister van de Kamer van Koophandel) under number 60673389. The condensed consolidated interim financial statements are comprised of Affimed N.V. and its controlled (and wholly owned) subsidiaries Affimed GmbH, Heidelberg, Germany, AbCheck s.r.o., Plzen, Czech Republic, and Affimed Inc., Delaware, USA (collectively “Affimed”, the “Company” or the “Group”). Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The Group’s product candidates are developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. Affimed has its own research and development programs, strategic collaborations and service contracts, where the Group is performing research services for third parties.

Basis of preparation and change

Basis of preparation and changes to Group's accounting policies	6 Months Ended
	Jun. 30, 2023
Basis of preparation and changes to Group's accounting policies
Basis of preparation and changes to Group's accounting policies	2. Basis of preparation and changes to Group’s accounting policies Statement of compliance The condensed consolidated interim financial statements (referred to as the “interim financial statements”) as of June 30, 2023 and December 31, 2022 and for the three and six months ended June 30, 2023 and 2022 have been prepared in accordance with IAS 34 Interim Financial Reporting. The interim financial statements do not include all the information and disclosures required in the consolidated annual financial statements and should be read in conjunction with Affimed N.V.’s annual consolidated financial statements as of December 31, 2022. The interim financial statements were authorized for issuance by the Company’s Management Board on August 10, 2023. Loss per share Loss per common share is calculated by dividing the loss for the period by the weighted average number of common shares outstanding during the period. As of June 30, 2023, the Group has granted 25,885,194 options and warrants in connection with share-based payment programs (see note 10) and a loan agreement, which could potentially have a dilutive effect but were excluded from the diluted weighted average number of ordinary shares calculation because their effect would have been anti-dilutive due to the net loss generated by the Group. Critical judgments and accounting estimates The preparation of the interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In preparing these interim financial statements, the critical judgments made by management in applying the Group’s accounting policies were the same as those that applied to the consolidated financial statements as of and for the year ended December 31, 2022. Functional and presentation currency These interim financial statements are presented in euro. The functional currency of the Group’s subsidiaries is also the euro. All financial information presented in euro has been rounded to the nearest thousand (abbreviated €) or million (abbreviated € million). Significant accounting policies The accounting policies applied by the Group in these interim financial statements are the same as those applied by the Group in its consolidated financial statements as of and for the year ended December 31, 2022. New standards and amendments to standards The following forthcoming standards and amendments to standards have not been applied in preparing these interim financial statements. ​ Standard/interpretation Effective Date 1 ​ ​ ​ Amendments to IAS 1 Presentation of Financial Statements: ​ ​ Classification of Liabilities as Current or Non-current ​ January 1, 2024 Amendments to IAS 1 Presentation of Financial Statements: ​ ​ Non- current Liabilities with Covenants ​ January 1, 2024 Amendments to IFRS 16 Leases: ​ ​ Lease Liability in a Sale and Leaseback ​ January 1, 2024 Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: ​ ​ Disclosures: Supplier Finance Arrangements ​ January 1, 2024 ​ The amended standards are not expected to have a significant effect on the interim financial statements of the Group. ​ Fair Value Measurement All assets and liabilities for which fair value is recognized in the interim financial statements are classified in accordance with the following fair value hierarchy, based on the lowest level input parameter that is significant on the whole for fair value measurement: ● Level 1 – Prices for identical assets or liabilities quoted in active markets (non-adjusted); ● Level 2 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market; and ● Level 3 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market. The carrying amount of all trade and other receivables, other assets and prepaid expenses, cash and cash equivalents, trade and other payables and loans is a reasonable approximation of the fair value and, therefore, information about the fair values of those financial instruments has not been disclosed. The measurement of the fair value of preferred and common shares in other companies held by the group is based on level 1 and 3 inputs (see note 5). The Group recognizes transfers between levels of the fair value hierarchy as the date at which the change has occurred. ​ 1 Shall apply for periods beginning on or after the date shown in the effective date column. ​ ​

Revenue

Revenue	6 Months Ended
	Jun. 30, 2023
Revenue
Revenue	3. Revenue Collaboration with Genentech Inc. In August 2018, Affimed entered into a strategic collaboration agreement with Genentech Inc. (Genentech), headquartered in South San Francisco, USA. Under the terms of the agreement, Affimed is providing services related to the development of novel NK cell engager-based immunotherapeutics to treat multiple cancers. The Genentech agreement became effective at the beginning of October 2018. Under the terms of the agreement, Affimed received $96.0 million ( €83.2 million) in initial upfront and committed funding on October 31, 2018. The Group recognized €0.2 million and €0.3 million as revenue during the three and six months ended June 30, 2023 (2022: €3.3 million and €7.3 million). As of the end of 2022, Affimed had completed work on and/or handed over all product candidates for further investigation by Genentech. The remaining revenue recognized during the six months ended June 30, 2023 relates to a platform license. As of June 30, 2023, the Group held contract liabilities of €1.4 million (December 31, 2022: €1.7 million), which will be recognized as revenue in subsequent periods. Under the terms of the agreement, Affimed is eligible to receive up to an additional $5.0 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones. Affimed is also eligible to receive royalties on any potential sales. Collaboration with Roivant Sciences Ltd. On November 9, 2020, Affimed and Affivant Sciences GmbH (formerly Pharmavant 6 GmbH), a subsidiary of Roivant Sciences Ltd. (Roivant), announced a strategic collaboration agreement which grants Roivant a license to the preclinical molecule AFM32. Under the terms of the agreement, Affimed received $60 million in upfront consideration, comprised of $40 million in cash and pre-funded research and development funding, and $20 million of common shares in Roivant. The Group is eligible to receive up to an additional $2 billion in milestone payments upon achievement of specified development, regulatory and commercial milestones, as well as tiered royalties on net sales. The Group recognized €1.1 million and €5.4 million as revenue during the three and six months ended June 30, 2023 (2022: €4.0 million and €7.9 million). As of June 30, 2023, the Group held contract liabilities of €3.3 million (December 31, 2022: €8.6 million), which will be recognized as revenue in subsequent periods as services are provided. Contract balances The following table provides information about receivables and contract liabilities from contracts with customers. ​ ​ ​ ​ ​ ​ ​ June 30, 2023 December 31, 2022 ​ ​ ​ ​ ​ Receivables 10 0 Contract liabilities 4,729 10,331 ​ An amount of €1.2 million and €5.7 million included in contract liabilities at the beginning of the period has been recognized as revenue during the three and six months ended June 30, 2023. The remaining performance obligations as of June 30, 2023 are approximately €4.7 million and are expected to be largely recognized as revenue over the next 12 months ( €4.0 million), with a smaller portion being realized thereafter ( €0.8 million). Disaggregation of revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ​ Three months ​ Six months ​ Six months ​ ​ ended ​ ended ​ ended ​ ended ​ June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Geographic information ​ ​ ​ ​ ​ ​ ​ ​ Revenue: Germany 0 14 0 151 USA 1,390 7,287 5,900 15,156 ​ ​ 1,390 7,301 5,900 15,307 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Major service lines: ​ ​ ​ ​ ​ ​ Collaboration revenue 1,215 7,284 5,671 15,153 Service revenue 175 17 229 154 ​ 1,390 7,301 5,900 15,307 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Timing on revenue recognition: ​ ​ ​ ​ ​ ​ ​ ​ Point in time 0 0 0 0 Over time 1,390 7,301 5,900 15,307 ​ 1,390 7,301 5,900 15,307 ​

Operating loss

Operating loss	6 Months Ended
	Jun. 30, 2023
Operating loss
Operating loss	4. Operating loss In April 2023, Affimed conducted a reorganization of its operations to focus on the Group’s three clinical stage development programs. As a result of the reorganization, the Group incurred a one-time expenditure for termination payments of €1.1 million during the three and six months ended June 30, 2023. Certain of these termination payments have already been settled and the balance will be settled in the second half of 2023. However, all of these termination payments have already been accrued for in calculating operating loss for the three and six months ended June 30,2023.

Finance income and finance cost

Finance income and finance costs	6 Months Ended
	Jun. 30, 2023
Finance income and finance costs
Finance income and finance costs	5. Finance income and finance costs ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended Three months ended Six months ended Six months ended ​ June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Interest SVB Loan Agreement (470) (381) (947) (759) Foreign exchange differences 121 2,653 (431) 3,568 Other finance income/finance costs - net 396 (19) 906 (85) ​ ​ 47 ​ 2,253 ​ (472) ​ 2,724 ​

Long-term financial assets

Long-term financial assets	6 Months Ended
	Jun. 30, 2023
Long-term financial assets
Long-term financial assets	6. Long- term financial assets The Group holds preferred shares in Amphivena, which are currently recognized at their fair value of nil . The impairment of the asset was recognized in 2021 based on the decision made by the board of Amphivena to wind down the company. Based on current information, we continue to estimate that the fair value remains at nil (December 31, 2022: nil ).

Trade and other receivables

Trade and other receivables	6 Months Ended
	Jun. 30, 2023
Trade and other receivables
Trade and other receivables	7 . Trade and other receivables The trade receivables as of June 30, 2023 were €10 (December 31, 2022: €0 ). These trade receivables are all due in the short-term, do not bear interest and are not impaired. Other receivables are all due within the short-term and mainly comprise value-added tax receivables of €0.9 million (December 31, 2022: €1.5 million).

Other assets and prepaid expens

Other assets and prepaid expenses	6 Months Ended
	Jun. 30, 2023
Other assets and prepaid expenses
Other assets and prepaid expenses	8 . Other assets and prepaid expenses The other assets and prepaid expenses as of June 30, 2023 of €7.9 million (December 31, 2022: €2.5 million) are short-term in nature, do not bear interest and are not impaired. The other assets and prepaid expenses mainly comprise a prepayment of €3.2 million for clinical trial management services and €0.7 million for reservation for toxicity study capacity (December 31, 2022: €1.1 million for the reservation of manufacturing capacity), a directors and officers’ liability insurance premium of €1.2 million (December 31, 2022: €0 million) and €1.5 million (December 31, 2022: €0.5 million) prepayment for assets secured for new premises.

Equity

Equity	6 Months Ended
	Jun. 30, 2023
Equity
Equity	9. Equity As of June 30, 2023, the share capital of €1,493 (December 31, 2022: €1,493 ) is comprised of 149,339,335 (December 31, 2022: 149,339,335 ) common shares with a par value of €0.01 per share. On April 18, 2022, the Company closed its public offering of 25,875,000 common shares (including over-allotment shares) at the public offering price of $4.00 per share, generating net proceeds of €89.8 million ( $97.1 million), after deducting €6.0 million ( $6.5 million) in underwriting commissions and other offering expenses.

Share-based payments

Share-based payments	6 Months Ended
	Jun. 30, 2023
Share-based payments
Share-based payments	10. Share-based payments In 2014, an equity-settled share-based payment program was established by Affimed N.V. (ESOP 2014). Under this program, the Company granted awards to certain members of the Management Board, certain members of the Company’s Supervisory Board, non-employee consultants and employees. Share-based payments with service conditions The majority of the awards vest in instalments over three years and can be exercised up to 10 years after the grant date. The Group granted 384,000 and 8,052,750 awards for the three and six months ended June 30, 2023 to employees, members of the Management Board and members of the Supervisory Board. Fair value of the awards at grant date in the three and six months ended June 30, 2023 amounts to €0.2 million ( $0.2 million) and €5.9 million ( $6.3 million). 217,725 and 368,540 ESOP 2014 awards were cancelled or forfeited due to termination of employment during the three and six months ended June 30, 2023 (June 30, 2022: 13,926 and 99,591 ). During the three and six months ended June 30, 2023, no options were exercised (June 30, 2022: 18,994 and 43,440 options at a weighted average share price of $2.26 and $2.52 ). As of June 30, 2023, 22,953,944 ESOP 2014 options were outstanding (December 31, 2022: 15,269,734 ), and 11,169,133 awards had vested (December 31, 2022: 8,510,863 ). The options outstanding as of June 30, 2023 had an exercise price in the range of $0.60 to $13.47 and a weighted average remaining contractual life of 7.7 years (December 31, 2022: 7.4 years) and a weighted average exercise price of $3.55 (December 31, 2022: $4.91) . Share-based payments with market condition During 2022, the Company issued 2,825,000 options ( 1,325,000 awards in the first quarter and 1,500,000 awards in the second quarter of 2022), with market-based performance conditions to members of the Management Board and employees. Each grant consists of three tranches, whereby one -third of the total grant will vest when the volume-weighted average share price over the preceding thirty trading days reaches $12.00 , $15.00 , and $18.00 , respectively. Except with respect to a change of control, these options shall not vest before the first anniversary of the grant date. As of June 30, 2023, no options were cancelled, forfeited or exercised. Fair value at grant date of the awards granted in the three and six months ended June 30, 2022 amounts to €1.4 million ( $1.8 million) and €2.9 million ( $3.2 million). The contractual lifetime of the options is two years . Any unvested awards on the date that is two years following the grant date will lapse. Share-based payment expense In the three and six months ended June 30, 2023, compensation expense of €3,231 (including an accelerated expense due to the reduction of the Company’s headcount in the course of the reorganization) and €7,389 was recognized affecting research and development expenses ( €1,709 and €4,022 ) and general and administrative expenses ( €1,523 and €3,368) . In the three and six months ended June 30, 2022, compensation expense of €5,625 and €9,872 was recognized affecting research and development expenses ( €2,889 and €5,194 ) and general and administrative expenses ( €2,736 and €4,678 ). Fair value measurement The fair value of options with service conditions granted in the six months ended June 30, 2023 and 2022, respectively, was determined using the Black-Scholes-Merton valuation model. The significant inputs into the valuation model are as follows (weighted average): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 June 30, 2022 ​ Fair value at grant date ​ $ 0.79 ​ $ 3.30 ​ Share price at grant date ​ $ 1.05 ​ $ 4.45 ​ Exercise price ​ $ 1.05 ​ $ 4.45 ​ Expected volatility ​ 90 % 90 % Expected life ​ 5.86 ​ 5.87 ​ Expected dividends ​ 0.00 ​ 0.00 ​ Risk-free interest rate ​ 3.95 % 2.22 % ​ The fair value of options with market conditions granted in the six months ended June 30, 2022, was determined using a Monte Carlo simulation. The significant inputs into the valuation model are as follows (weighted average): ​ ​ ​ ​ ​ ​ ​ June 30, 2022 Fair value at grant date ​ $ 1.13 ​ Share price at grant date ​ $ 4.58 ​ Exercise price ​ $ 4.58 ​ Expected volatility ​ 70 % Expected life ​ 2.00 ​ Expected dividends ​ 0.00 ​ Risk-free interest rate ​ 2.41 % ​ Expected volatility is estimated based on the observed daily share price returns of Affimed measured over a historic period equal to the expected life of the awards. The risk-free interest rates are based on the yield to maturity of U.S. Treasury strips (as best available indication for risk-free rates), for a term equal to the expected life, as measured as of the grant date.

Borrowings

Borrowings	6 Months Ended
	Jun. 30, 2023
Borrowings
Borrowings	11. Borrowings Silicon Valley Bank In January 2021, the Group entered into a new loan agreement with Silicon Valley Bank German Branch (now: Silicon Valley Bridge Bank N.A. Germany Branch) or “SVB” which provides Affimed with up to €25 million in term loans in three tranches: €10 million available at closing, an additional €7.5 million upon the achievement of certain conditions, including milestones related to Affimed’s pipeline and market capitalization, and a third tranche of €7.5 million upon the achievement of certain additional conditions related to Affimed’s pipeline and liquidity. The first tranche of €10 million was drawn in February 2021 and the second tranche of €7.5 million in December 2021. Pursuant to the terms of the agreement, the loan bears interest at the greater of the European Central Bank Base Rate and 0% , plus 5.5% . Affimed was entitled to make interest only payments through December 1, 2022. The loan will mature at the end of November 2025. As of June 30, 2023, the fair value of the liability did not differ significantly from its carrying amount. The loan is secured by a pledge of 100% of the Group’s ownership interest in Affimed GmbH, all intercompany claims owed to Affimed N.V. by its subsidiaries, and collateral agreements for all bank accounts, inventory, trade receivables and other receivables of Affimed N.V. and Affimed GmbH recognized in the interim financial statements. In July 2023, Bootstrap Europe announced the acquisition of SVB. The loan agreement is expected to be transferred to Bootstrap Europe with no change in the terms of the loan agreement. UniCredit Leasing CZ In April 2019, the Group entered into a loan agreement with UniCredit Leasing CZ for €562 . After an initial instalment of €127 in the second quarter of 2019, repayment is effected in monthly instalments of €8 until May 2024. As of June 30, 2023, an amount of €89 (December 31, 2022: €136 ) was outstanding, of which €89 was classified as current liabilities (December 31, 2022: €96 ). As of June 30, 2023, the fair value of the liability did not differ significantly from its carrying amount.

Related parties

Related parties	6 Months Ended
	Jun. 30, 2023
Related parties
Related parties	12. Related parties The supervisory board directors of Affimed N.V. received compensation in the amounts of €114 and €238 ( €107 and €216 ) for their services on the Supervisory Board in the three and six months ended June 30, 2023 (2022). Members of the Management Board received compensation in the amounts of €972 and €1,916 ( €936 and €1,829 ) for their services on the Management Board in the three and six months ended June 30, 2023 (2022). The Company recognized share-based payment expenses of €83 and €195 ( €719 and €998 ) for supervisory directors and €1,317 and €2,954 ( €1,816 and €3,389 ) for managing directors in the three and six months ended June 30, 2023 (2022). The following table provides the total amounts of outstanding balances for supervisory board compensation and expense reimbursement related to key management personnel: ​ ​ ​ ​ ​ ​ ​ ​ Outstanding balances ​ ​ June 30, ​ December 31, ​ 2023 2022 Adi Hoess - 1 Wolfgang Fischer ​ - ​ 2 Arndt Schottelius ​ - ​ 3 Thomas Hecht 20 21 Mathieu Simon 9 10 Ulrich Grau 22 26 Bernhard Ehmer ​ 12 ​ 17 Harry Welten ​ 9 ​ 8 Annalisa Jenkins ​ 11 ​ 11 Uta Kemmerich-Keil 17 18 Constanze Ulmer-Eilfort ​ 5 ​ - ​

Basis of preparation and chan_2

Basis of preparation and changes to Group's accounting policies (Policies)	6 Months Ended
	Jun. 30, 2023
Basis of preparation and changes to Group's accounting policies
Statement of compliance	Statement of compliance The condensed consolidated interim financial statements (referred to as the “interim financial statements”) as of June 30, 2023 and December 31, 2022 and for the three and six months ended June 30, 2023 and 2022 have been prepared in accordance with IAS 34 Interim Financial Reporting. The interim financial statements do not include all the information and disclosures required in the consolidated annual financial statements and should be read in conjunction with Affimed N.V.’s annual consolidated financial statements as of December 31, 2022. The interim financial statements were authorized for issuance by the Company’s Management Board on August 10, 2023.
Loss per share	Loss per share Loss per common share is calculated by dividing the loss for the period by the weighted average number of common shares outstanding during the period. As of June 30, 2023, the Group has granted 25,885,194 options and warrants in connection with share-based payment programs (see note 10) and a loan agreement, which could potentially have a dilutive effect but were excluded from the diluted weighted average number of ordinary shares calculation because their effect would have been anti-dilutive due to the net loss generated by the Group.
Critical judgments and accounting estimates	Critical judgments and accounting estimates The preparation of the interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In preparing these interim financial statements, the critical judgments made by management in applying the Group’s accounting policies were the same as those that applied to the consolidated financial statements as of and for the year ended December 31, 2022.
Functional and presentation currency	Functional and presentation currency These interim financial statements are presented in euro. The functional currency of the Group’s subsidiaries is also the euro. All financial information presented in euro has been rounded to the nearest thousand (abbreviated €) or million (abbreviated € million).
Significant accounting policies	Significant accounting policies The accounting policies applied by the Group in these interim financial statements are the same as those applied by the Group in its consolidated financial statements as of and for the year ended December 31, 2022.
New standards and amendments to standards	New standards and amendments to standards The following forthcoming standards and amendments to standards have not been applied in preparing these interim financial statements. ​ Standard/interpretation Effective Date 1 ​ ​ ​ Amendments to IAS 1 Presentation of Financial Statements: ​ ​ Classification of Liabilities as Current or Non-current ​ January 1, 2024 Amendments to IAS 1 Presentation of Financial Statements: ​ ​ Non- current Liabilities with Covenants ​ January 1, 2024 Amendments to IFRS 16 Leases: ​ ​ Lease Liability in a Sale and Leaseback ​ January 1, 2024 Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: ​ ​ Disclosures: Supplier Finance Arrangements ​ January 1, 2024 ​ The amended standards are not expected to have a significant effect on the interim financial statements of the Group.
Fair Value Measurement	Fair Value Measurement All assets and liabilities for which fair value is recognized in the interim financial statements are classified in accordance with the following fair value hierarchy, based on the lowest level input parameter that is significant on the whole for fair value measurement: ● Level 1 – Prices for identical assets or liabilities quoted in active markets (non-adjusted); ● Level 2 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market; and ● Level 3 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market. The carrying amount of all trade and other receivables, other assets and prepaid expenses, cash and cash equivalents, trade and other payables and loans is a reasonable approximation of the fair value and, therefore, information about the fair values of those financial instruments has not been disclosed. The measurement of the fair value of preferred and common shares in other companies held by the group is based on level 1 and 3 inputs (see note 5). The Group recognizes transfers between levels of the fair value hierarchy as the date at which the change has occurred. ​ 1 Shall apply for periods beginning on or after the date shown in the effective date column. ​

Basis of preparation and chan_3

Basis of preparation and changes to Group's accounting policies (Tables)	6 Months Ended
	Jun. 30, 2023
Basis of preparation and changes to Group's accounting policies
Schedule of new standards and amendments to standards	​ Standard/interpretation Effective Date 1 ​ ​ ​ Amendments to IAS 1 Presentation of Financial Statements: ​ ​ Classification of Liabilities as Current or Non-current ​ January 1, 2024 Amendments to IAS 1 Presentation of Financial Statements: ​ ​ Non- current Liabilities with Covenants ​ January 1, 2024 Amendments to IFRS 16 Leases: ​ ​ Lease Liability in a Sale and Leaseback ​ January 1, 2024 Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: ​ ​ Disclosures: Supplier Finance Arrangements ​ January 1, 2024

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue
Schedule of receivables and contract liabilities from contracts with customers	​ ​ ​ ​ ​ ​ ​ June 30, 2023 December 31, 2022 ​ ​ ​ ​ ​ Receivables 10 0 Contract liabilities 4,729 10,331
Schedule of disaggregation of revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ​ Three months ​ Six months ​ Six months ​ ​ ended ​ ended ​ ended ​ ended ​ June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Geographic information ​ ​ ​ ​ ​ ​ ​ ​ Revenue: Germany 0 14 0 151 USA 1,390 7,287 5,900 15,156 ​ ​ 1,390 7,301 5,900 15,307 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Major service lines: ​ ​ ​ ​ ​ ​ Collaboration revenue 1,215 7,284 5,671 15,153 Service revenue 175 17 229 154 ​ 1,390 7,301 5,900 15,307 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Timing on revenue recognition: ​ ​ ​ ​ ​ ​ ​ ​ Point in time 0 0 0 0 Over time 1,390 7,301 5,900 15,307 ​ 1,390 7,301 5,900 15,307

Finance income and finance co_2

Finance income and finance costs (Tables)	6 Months Ended
	Jun. 30, 2023
Finance income and finance costs
Schedule of finance income and finance costs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended Three months ended Six months ended Six months ended ​ June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Interest SVB Loan Agreement (470) (381) (947) (759) Foreign exchange differences 121 2,653 (431) 3,568 Other finance income/finance costs - net 396 (19) 906 (85) ​ ​ 47 ​ 2,253 ​ (472) ​ 2,724

Share-based payments (Tables)

Share-based payments (Tables)	6 Months Ended
	Jun. 30, 2023
Share-based payments with service condition
Share-based payments
Schedule of fair value of options	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 June 30, 2022 ​ Fair value at grant date ​ $ 0.79 ​ $ 3.30 ​ Share price at grant date ​ $ 1.05 ​ $ 4.45 ​ Exercise price ​ $ 1.05 ​ $ 4.45 ​ Expected volatility ​ 90 % 90 % Expected life ​ 5.86 ​ 5.87 ​ Expected dividends ​ 0.00 ​ 0.00 ​ Risk-free interest rate ​ 3.95 % 2.22 %
Share-based payments with market condition
Share-based payments
Schedule of fair value of options	​ ​ ​ ​ ​ ​ ​ June 30, 2022 Fair value at grant date ​ $ 1.13 ​ Share price at grant date ​ $ 4.58 ​ Exercise price ​ $ 4.58 ​ Expected volatility ​ 70 % Expected life ​ 2.00 ​ Expected dividends ​ 0.00 ​ Risk-free interest rate ​ 2.41 %

Related parties (Tables)

Related parties (Tables)	6 Months Ended
	Jun. 30, 2022
Related parties
Outstanding balances for supervisory board compensation and expense reimbursement related to key management personnel	​ ​ ​ ​ ​ ​ ​ ​ Outstanding balances ​ ​ June 30, ​ December 31, ​ 2023 2022 Adi Hoess - 1 Wolfgang Fischer ​ - ​ 2 Arndt Schottelius ​ - ​ 3 Thomas Hecht 20 21 Mathieu Simon 9 10 Ulrich Grau 22 26 Bernhard Ehmer ​ 12 ​ 17 Harry Welten ​ 9 ​ 8 Annalisa Jenkins ​ 11 ​ 11 Uta Kemmerich-Keil 17 18 Constanze Ulmer-Eilfort ​ 5 ​ -

Basis of preparation and chan_4

Basis of preparation and changes to Group's accounting policies (Details)	6 Months Ended
	Jun. 30, 2023 shares
Basis of preparation and changes to Group's accounting policies
Number of shares excluded from calculation of earnings per share because their effect would have been anti-dilutive	25,885,194

Basis of preparation and chan_5

Basis of preparation and changes to Group's accounting policies - New standards and amendments to standards (Details)	6 Months Ended
	Jun. 30, 2023
Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current
Basis of preparation and changes to Group's accounting policies
Standard/interpretation	Classification of Liabilities as Current or Non-current
Effective Date	Jan. 01, 2024
Amendments to IAS 1 Presentation of Financial Statements: Non-current Liabilities with Covenants
Basis of preparation and changes to Group's accounting policies
Standard/interpretation	Non-current Liabilities with Covenants
Effective Date	Jan. 01, 2024
Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback
Basis of preparation and changes to Group's accounting policies
Standard/interpretation	Lease Liability in a Sale and Leaseback
Effective Date	Jan. 01, 2024
Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments, Disclosures: Supplier Finance Arrangements
Basis of preparation and changes to Group's accounting policies
Standard/interpretation	Disclosures: Supplier Finance Arrangements
Effective Date	Jan. 01, 2024

Revenue - Additional Informatio

Revenue - Additional Information (Details) € in Millions, $ in Millions		1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Nov. 09, 2020 USD ($)	Oct. 31, 2018 USD ($)	Oct. 31, 2018 EUR (€)	Jun. 30, 2023 EUR (€)	Jun. 30, 2022 EUR (€)	Jun. 30, 2023 EUR (€)	Jun. 30, 2022 EUR (€)	Dec. 31, 2022 EUR (€)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 EUR (€)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue under contract liabilities				€ 1.2		€ 5.7
Remaining performance obligations										€ 4.7
Remaining performance obligation period						12 months
Performance obligations description						The remaining performance obligations as of June 30, 2023 are approximately €4.7 million and are expected to be largely recognized as revenue over the next 12 months (€4.0 million), with a smaller portion being realized thereafter (€0.8 million).
Over the next 12 months
Disclosure of disaggregation of revenue from contracts with customers [line items]
Remaining performance obligations										4
12 months thereafter
Disclosure of disaggregation of revenue from contracts with customers [line items]
Remaining performance obligations										€ 0.8
Genentech Inc
Disclosure of disaggregation of revenue from contracts with customers [line items]
Collaboration agreement initial upfront consideration		$ 96	€ 83.2
Revenue				0.2	€ 3.3	€ 0.3	€ 7.3
Revenue under contract liabilities						1.4		€ 1.7
Additional payments upon achievement of milestones | $									$ 5,000
Roivant Sciences Ltd.
Disclosure of disaggregation of revenue from contracts with customers [line items]
Collaboration agreement initial upfront consideration | $	$ 60
Revenue				€ 1.1	€ 4	5.4	€ 7.9
Revenue under contract liabilities						€ 3.3		€ 8.6
Additional payments upon achievement of milestones | $	2,000
Collaboration agreement cash consideration | $	40
Collaboration agreement consideration in shares | $	$ 20

Revenue (Details)

Revenue (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Revenue
Receivables	€ 10	€ 0
Contract liabilities	€ 4,729	€ 10,331

Revenue - Disaggregation of rev

Revenue - Disaggregation of revenue (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue
Revenues	€ 1,390	€ 7,301	€ 5,900	€ 15,307
Germany
Revenue
Revenues	0	14	0	151
USA
Revenue
Revenues	1,390	7,287	5,900	15,156
Point in time
Revenue
Revenues	0	0	0	0
Over time
Revenue
Revenues	1,390	7,301	5,900	15,307
Collaboration
Revenue
Revenues	1,215	7,284	5,671	15,153
Service
Revenue
Revenues	€ 175	€ 17	€ 229	€ 154

Operating loss (Details)

Operating loss (Details) - EUR (€) € in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Operating loss
Termination payments	€ 1.1	€ 1.1

Finance income and finance co_3

Finance income and finance costs (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disclosure of Finance Income and Finance Costs Line Items]
Finance income/costs - net	€ 47	€ 2,253	€ (472)	€ 2,724
Interest SVB Loan Agreement
Disclosure of Finance Income and Finance Costs Line Items]
Finance income/costs - net	(470)	(381)	(947)	(759)
Foreign exchange differences
Disclosure of Finance Income and Finance Costs Line Items]
Finance income/costs - net	121	2,653	(431)	3,568
Other finance income/finance costs - net
Disclosure of Finance Income and Finance Costs Line Items]
Finance income/costs - net	€ 396	€ (19)	€ 906	€ (85)

Long-term financial assets (Det

Long-term financial assets (Details) - Preferred Shares - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Long-term financial assets
Fair value of shares	€ 0
Fair value shares of remaining	€ 0	€ 0

Trade and other receivables (De

Trade and other receivables (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Trade and other receivables
Trade receivables	€ 10	€ 0
Value added tax receivables	€ 900	€ 1,500

Other assets and prepaid expe_2

Other assets and prepaid expenses (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Other assets and prepaid expenses
Other assets and prepaid expenses	€ 7,932	€ 2,459
Prepayment for Directors and Officers' liability insurance premium	1,200	0
Reservation of manufacturing capacity
Other assets and prepaid expenses
Prepayment for reservation of manufacturing capacity		1,100
Assets secured for the new premises
Other assets and prepaid expenses
Prepayments	1,500	€ 500
Clinical trial management services
Other assets and prepaid expenses
Prepayment for reservation of manufacturing capacity	3,200
Reservation for toxicity study capacity
Other assets and prepaid expenses
Prepayment for reservation of manufacturing capacity	€ 700

Equity (Details)

Equity (Details) € / shares in Units, $ / shares in Units, € in Thousands, $ in Millions			6 Months Ended
	Apr. 18, 2022 EUR (€) shares	Apr. 18, 2022 USD ($) $ / shares shares	Jun. 30, 2023 EUR (€) € / shares shares	Jun. 30, 2022 EUR (€)	Dec. 31, 2022 EUR (€) € / shares shares
Issued capital | €			€ 1,493		€ 1,493
Number of shares outstanding | shares			149,339,335		149,339,335
Par value | € / shares			€ 0.01		€ 0.01
Net proceeds from issue of common shares | €			€ 0	€ 95,907
Public offering
Number of shares issued | shares	25,875,000	25,875,000
Net proceeds from issue of common shares	€ 89,800	$ 97.1
Share price | $ / shares		$ 4
Underwriting commissions, legal and consulting expenses	€ 6,000	$ 6.5

Share-based payments - Fair val

Share-based payments - Fair value of options (Details)	6 Months Ended
	Jun. 30, 2023 USD ($) Y $ / shares	Jun. 30, 2022 USD ($) Y EUR (€) $ / shares
Share-based payments with service condition
Share-based payments
Fair value at grant date | $	$ 0.79	$ 3.30
Share price at grant date | $ / shares	$ 1.05	$ 4.45
Exercise price | $ / shares	$ 1.05	$ 4.45
Expected volatility	90%	90%
Expected life | Y	5.86	5.87
Expected dividends | $	$ 0	$ 0
Risk-free interest rate	3.95%	2.22%
Share-based payments with market condition
Share-based payments
Fair value at grant date | $		$ 1.13
Share price at grant date | $ / shares		$ 4.58
Exercise price | $ / shares		$ 4.58
Expected volatility		70%
Expected life | €		2
Expected dividends | $		$ 0
Risk-free interest rate		2.41%

Share-based payments - Service

Share-based payments - Service conditions (Details) $ / shares in Units, $ in Millions	3 Months Ended			6 Months Ended			12 Months Ended
	Jun. 30, 2023 EUR (€) EquityInstruments shares	Jun. 30, 2023 USD ($) EquityInstruments $ / shares shares	Jun. 30, 2022 EquityInstruments $ / shares shares	Jun. 30, 2023 EUR (€) EquityInstruments shares	Jun. 30, 2023 USD ($) EquityInstruments $ / shares shares	Jun. 30, 2022 EquityInstruments $ / shares shares	Dec. 31, 2022 EquityInstruments $ / shares
Share-based payments with service condition
Awards cancelled or forfeited | €				0
ESOP 2014
Share-based payments with service condition
Vesting period (in years)				3 years	3 years
Exercise period				10 years	10 years
Awards granted | EquityInstruments	384,000	384,000		8,052,750	8,052,750
Fair value of the awards at grant date	€ 200,000	$ 0.2		€ 5,900,000	$ 6.3
Awards cancelled or forfeited | EquityInstruments	217,725	217,725	13,926	368,540	368,540	99,591
Awards exercised | shares	0	0	18,994	0	0	43,440
Weighted average exercise price of awards exercised					$ 3.55		$ 4.91
Awards outstanding | EquityInstruments		22,953,944			22,953,944		15,269,734
Awards vested | EquityInstruments				11,169,133	11,169,133		8,510,863
Weighted average remaining contractual life				7 years 8 months 12 days	7 years 8 months 12 days		7 years 4 months 24 days
ESOP 2014 | Minimum
Share-based payments with service condition
Weighted average exercise price of awards exercised			$ 2.26
Exercise price		$ 0.60			$ 0.60
ESOP 2014 | Maximum
Share-based payments with service condition
Weighted average exercise price of awards exercised						$ 2.52
Exercise price		$ 13.47			$ 13.47

Share-based payments - Market c

Share-based payments - Market condition (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022 shares	Mar. 31, 2022 shares	Jun. 30, 2023 EUR (€) tranche $ / shares	Jun. 30, 2022 shares
Share-based payments with market condition
Number of options issued | shares	1,500,000	1,325,000		2,825,000
Number of tranches | tranche			3
Awards cancelled or forfeited | €			0
Trading days			30 days
Contractual lifetime of the options				2 years
Tranche I
Share-based payments with market condition
Hurdle rate			$ 12
Tranche II
Share-based payments with market condition
Hurdle rate			15
Tranche III
Share-based payments with market condition
Hurdle rate			$ 18

Share-based payments - Payment

Share-based payments - Payment expense (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-based payments
Share-based expense	€ 3,231	€ 5,625	€ 7,389	€ 9,872
Research and Development
Share-based payments
Share-based expense	1,709	2,889	4,022	5,194
General and Administrative
Share-based payments
Share-based expense	€ 1,523	€ 2,736	€ 3,368	€ 4,678

Share-based payments - Addition

Share-based payments - Additional Information (Details) $ / shares in Units, $ in Millions	3 Months Ended					6 Months Ended				12 Months Ended
	Jun. 30, 2023 EUR (€) EquityInstruments shares	Jun. 30, 2023 USD ($) EquityInstruments $ / shares shares	Jun. 30, 2022 EUR (€) EquityInstruments shares	Jun. 30, 2022 USD ($) EquityInstruments $ / shares shares	Mar. 31, 2022 shares	Jun. 30, 2023 EUR (€) EquityInstruments tranche shares	Jun. 30, 2023 USD ($) EquityInstruments tranche $ / shares shares	Jun. 30, 2022 EUR (€) EquityInstruments shares	Jun. 30, 2022 USD ($) EquityInstruments $ / shares shares	Dec. 31, 2022 EquityInstruments $ / shares
Share-based payments
Awards cancelled or forfeited | €						0
Number of options issued | shares			1,500,000	1,500,000	1,325,000			2,825,000	2,825,000
Number of tranches | tranche						3	3
Trading days						30 days	30 days
Contractual lifetime of the options								2 years	2 years
Share-based expense | €	€ 3,231,000		€ 5,625,000			€ 7,389,000		€ 9,872,000
Vesting percentage						0.33%	0.33%
Tranche I
Share-based payments
Hurdle rate							$ 12
Tranche II
Share-based payments
Hurdle rate							15
Tranche III
Share-based payments
Hurdle rate							$ 18
Research and Development
Share-based payments
Share-based expense | €	1,709,000		2,889,000			€ 4,022,000		5,194,000
General and Administrative
Share-based payments
Share-based expense | €	€ 1,523,000		€ 2,736,000			€ 3,368,000		€ 4,678,000
ESOP 2014
Share-based payments
Vesting period (in years)						3 years	3 years
Exercise period						10 years	10 years
Awards granted | EquityInstruments	384,000	384,000				8,052,750	8,052,750
Fair value of the awards at grant date	€ 200,000	$ 0.2				€ 5,900,000	$ 6.3
Awards cancelled or forfeited | EquityInstruments	217,725	217,725	13,926	13,926		368,540	368,540	99,591	99,591
Awards exercised | shares	0	0	18,994	18,994		0	0	43,440	43,440
Weighted average exercise price of awards exercised							$ 3.55			$ 4.91
Awards outstanding | EquityInstruments		22,953,944					22,953,944			15,269,734
Awards vested | EquityInstruments						11,169,133	11,169,133			8,510,863
Weighted average remaining contractual life						7 years 8 months 12 days	7 years 8 months 12 days			7 years 4 months 24 days
Grant date fair value			€ 1,400,000	$ 1.8				€ 2,900,000	$ 3.2
ESOP 2014 | Minimum
Share-based payments
Weighted average exercise price of awards exercised				$ 2.26
Exercise price		$ 0.60					$ 0.60
ESOP 2014 | Maximum
Share-based payments
Weighted average exercise price of awards exercised									$ 2.52
Exercise price		$ 13.47					$ 13.47

Borrowings - Additional Informa

Borrowings - Additional Information (Details) - EUR (€) € in Thousands	1 Months Ended		3 Months Ended	6 Months Ended
	Dec. 31, 2021	Feb. 28, 2021	Jun. 30, 2019	Jun. 30, 2023	Dec. 31, 2022	Jan. 31, 2021	Apr. 30, 2019
Loan agreement with UniCredit Leasing CZ
Borrowings
Amount outstanding				€ 89	€ 136		€ 562
Loan repaid			€ 127
Monthly repayment instalment							€ 8
Current liabilities				€ 89	€ 96
Silicon Valley Bank Loan
Borrowings
Percentage of ownership interest pledged as security				100%
SVB Loan Agreement | Loan facility trance one
Borrowings
Term loans						€ 10,000
Amount drawdown		€ 10,000
SVB Loan Agreement | Loan facility trance two
Borrowings
Term loans						7,500
Amount drawdown	€ 7,500
SVB Loan Agreement | Loan facility trance three
Borrowings
Term loans						€ 7,500
Minimum | EURIBOR
Borrowings
Variable interest rate						0%
Maximum
Borrowings
Variable interest rate						5.50%
Maximum | SVB Loan Agreement
Borrowings
Term loans						€ 25,000

Related parties - Outstanding B

Related parties - Outstanding Balances (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Adi Hoess
Related parties
Key management personnel outstanding balance		€ 1
Wolfgang Fischer
Related parties
Key management personnel outstanding balance		2
Arndt Schottelius
Related parties
Key management personnel outstanding balance		3
Thomas Hecht
Related parties
Key management personnel outstanding balance	€ 20	21
Mathieu Simon
Related parties
Key management personnel outstanding balance	9	10
Ulrich Grau
Related parties
Key management personnel outstanding balance	22	26
Bernhard Ehmer
Related parties
Key management personnel outstanding balance	12	17
Harry Welten
Related parties
Key management personnel outstanding balance	9	8
Annalisa Jenkins
Related parties
Key management personnel outstanding balance	11	11
Uta Kemmerich-Kell
Related parties
Key management personnel outstanding balance	17	€ 18
Constanze Ulmer-Eilfort
Related parties
Key management personnel outstanding balance	€ 5

Related parties - Additional In

Related parties - Additional Information (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Related parties
Share-based expense	€ 3,231	€ 5,625	€ 7,389	€ 9,872
Supervisory Board Directors
Related parties
Compensation received for their services	114	107	238	216
Share-based expense	83	719	195	998
Management Board
Related parties
Compensation received for their services	972	936	1,916	1,829
Share-based expense	€ 1,317	€ 1,816	€ 2,954	€ 3,389